Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

February 24, 2022

NASDAQ US Health Care Biotechnology earnings 81 min

Earnings Call Speaker Segments

Joanna Siegall

executive
#1

Thank you. Good afternoon, everyone, and we appreciate your participation in today's call. Robert Blum, our President and Chief Executive Officer, will kick things off with a short summary of the quarter along with recent developments. Following that, Fady Malik, EVP of R&D, will share updates concerning omecamtiv mecarbil and CK-136. Stuart Kupfer, SVP and Chief Medical Officer, will then give an update on aficamten and reldesemtiv. Andrew Callos, EVP and Chief Commercial Officer, will talk about commercialization planning activities for omecamtiv mecarbil. Robert Wong, VP and Chief Accounting Officer, will walk through a financial overview for the quarter just ended; and Ching Jaw, SVP and Chief Financial Officer, will cover our 2022 financial guidance as well as corporate development strategies. Last, Robert Blum will offer closing comments and go over expected key milestones for 2022. Be aware that parts of the discussion that follows, including our answers to questions, include statements tied to future events and performance instead of historical facts, and these constitute forward-looking statements. Results we actually achieve could differ materially from what those forward-looking statements project. Details about factors that might lead our actual results to diverge materially from what is expressed in these forward-looking statements can be found in our SEC filings, among them our current report on our fourth quarter 2021 financial results, submitted today on Form 8-K. We assume no duty to revise any forward-looking statements once this call concludes. I'll now hand the call over to Robert.

Robert Blum

executive
#2

Thanks, Joanna, and once more I appreciate all of you being with us on today's call. Our fourth quarter was quite productive, with further favorable developments and momentum carrying over into the opening stretch of this year. The biggest item: we said recently that the FDA has accepted for filing our NDA for omecamtiv mecarbil, and that comes with a PDUFA date of November 30, 2022. That marks a thrilling step for our organization, one that dozens of clinical trials, thousands of people enrolled in those trials, and years of commitment from Cytokinetics staff have made achievable; we also reported results from METEORIC-HF, where treatment with omecamtiv mecarbil versus placebo failed to demonstrate an effect on exercise capacity among patients receiving standard of care medical therapy. Naturally that outcome leaves us disappointed, yet the NDA now on file with the FDA rests on findings from GALACTIC-HF, and because the safety profile matched what earlier clinical trials showed, we don't anticipate METEORIC-HF findings affecting any potential approval of omecamtiv mecarbil. Now to aficamten. Throughout 2021 and once more already in 2022, this program has moved forward considerably. In the quarter, the FDA granted breakthrough therapy designation for aficamten, and the Center for Drug Evaluation of the National Medical Products Administration in China likewise awarded breakthrough therapy designation for aficamten to treat symptomatic obstructive HCM. On top of that, only yesterday we told you that SEQUOIA-HCM, our Phase III clinical trial of aficamten in symptomatic obstructive HCM patients, is now open for enrollment; we also recently reported top line results from Cohort 3 of REDWOOD-HCM among patients on disopyramide, which supports putting this patient population into SEQUOIA-HCM. A bit later on this call, Stuart will walk through our plans to broaden the aficamten development program through added trials starting this year. In Q4 we likewise moved earlier-stage research programs into IND-enabling studies, and we intend to push ahead with clinical development of CK-136, our cardiac troponin activator. In a moment Fady will discuss our goals for this novel mechanism program further. What stands behind our recent wins and sustains our ambitious targets for this year are our solid balance sheet and funding commitments amounting collectively to more than 2 years of cash runway, reinforced by 2 recent transactions that Ching will describe in greater detail; our company is entering a thrilling new period; we've kept growing our team and are establishing new capabilities ahead of the possible approval and anticipated launch of omecamtiv mecarbil. Simultaneously, we've kept working across our pipeline of late-stage programs involving aficamten and reldesemtiv plus earlier stage programs such as CK-136 and our preclinical work, all of which are moving forward. Today we're eager to bring you updates covering all these programs along with our anticipated milestones for the year. So with that, I'll hand the call to Fady, who will go deeper first on recent developments tied to omecamtiv mecarbil and CK-136.

Fady Malik

executive
#3

Thank you, Robert. Seven days ago, we shared the topline findings from METEORIC-HF, which assessed how 20 weeks of therapy using omecamtiv mecarbil, versus placebo, affected exercise capacity. In this study of 276 patients, the primary endpoint showed no impact — that endpoint being the shift in peak oxygen uptake, or peak VO2, measured through cardiopulmonary exercise testing between baseline and week 20. Adverse events looked comparable across the treatment groups, and it's worth highlighting that this trial enrolled a lower-risk population than GALACTIC-HF did, and tested a separate hypothesis — boosting exercise capacity rather than lowering the likelihood of clinical outcomes. Although medical treatments have shown meaningful decreases in the danger of poor clinical outcomes among heart failure patients with reduced ejection fraction — something also seen with omecamtiv mecarbil and GALACTIC-HF — proving that those same treatments improve exercise capacity has remained out of reach. METEORIC-HF was a very well-executed study, carried out under difficult conditions because of the pandemic. I'd like to congratulate the study team and the investigators for seeing this trial through, and also thank the patients who took part. The complete results, currently under embargo, are set to be presented at the ACC scientific session as a late-breaking clinical trial in April; meanwhile, we're still seeking further insights from GALACTIC-HF. During the fourth quarter, we shared findings from a post-hoc analysis indicating that omecamtiv mecarbil treatment was tied to a meaningful drop in stroke risk. That decrease could stem from fewer adverse events of atrial fibrillation or flutter, along with gains in atrial and ventricular function that have been seen in GALACTIC-HF and in earlier clinical trials of omecamtiv mecarbil. At the ACC scientific session coming up in April, we're eager to share fresh analyses from GALACTIC-HF that compare omecamtiv mecarbil's effect across prespecified subgroups of hospitalized versus outpatient patients, and in addition, our health economics and outcomes research colleagues, working alongside Dr. Nihar Desai from the Yale School of Medicine and others, will present data regarding heart failure's impact on health care resource utilization, plus the related intensity and cost for patients in GALACTIC-HF. As Robert noted, FDA is reviewing the NDA for omecamtiv mecarbil, with a PDUFA date of November 30, 2022. I'd like to pause and congratulate and thank everyone who contributed to this filing, since it reflects many years of commitment toward pursuing an innovative hypothesis for the potential benefit of heart failure patients. Now, returning to pre-commercialization efforts for omecamtiv mecarbil. On the medical affairs front, during the fourth quarter, we kept growing both the size and leadership of our therapeutic medical scientist team, and we also started building our managed health care medical science team; additionally, we finished vendor selection for the medical contact center and wrapped up the governance and design of our investigator-sponsored study program. Our medical affairs group is going to keep up its key educational efforts, which support a possible launch for omecamtiv mecarbil as outlined in the 2022 strategic plan we've put together. Now moving on to CK-136, an investigational novel cardiac troponin activator we're studying. This quarter, we shared preclinical findings tied to how it was discovered and optimized. We additionally presented and published preclinical results for a CK-136 analog, demonstrating a rise in contractility with no adverse effects on myocardial energetics; planning has begun on our side to make it possible to move the CK-136 development program forward prior to the close of this year. Given how CK-136 works and our intention to study its possible safety and efficacy in neighboring populations with unmet need, including heart failure with right ventricular dysfunction, it could end up differentiated from omecamtiv mecarbil. Having said that, I'll hand things over to Stuart for an update on aficamten and reldesemtiv.

Stuart Kupfer

executive
#4

Thank you, Fady. We were happy to report during this quarter that the FDA has awarded breakthrough therapy designation to aficamten for treating symptomatic obstructive HCM, and that decision rested mostly on results produced by the Phase II clinical trial known as Redwood-HCM. HCM is still a condition where needs go largely unmet, since few therapies exist for patients who frequently deal with numerous symptoms that interfere with their everyday quality of life. A few weeks back, we also reported top line data from Cohort 3 of Redwood HCM, which studied individuals with obstructive HCM who remained refractory even after receiving disopyramide, the last line of medical therapy. Those results demonstrated that meaningful reductions occurred in the average resting and post-Valsalva left ventricular outflow tract gradients; such declines came about alongside only modest drops in average LV ejection fraction, and not a single patient's ejection fraction dropped beneath the prespecified safety threshold of 50%. Aficamten's pharmacokinetics along with its safety and tolerability profile matched what had been seen previously in Redwood-HCM, and no treatment interruptions took place. We're eager to present Cohort 3's complete findings at the ACC Annual Scientific Session in April. Yesterday, we were happy to announce that enrollment has opened in Sequoia-HCM, the Phase III registrational trial for aficamten. Sequoia-HCM is a randomized, double-blind, placebo-controlled international clinical trial whose design compares 24 weeks of aficamten or placebo treatment among patients with symptomatic obstructive HCM who have a substantial outflow track gradient even with background medical therapy. The main goal is assessing the change from baseline to week 24 in peak VO2, measured through CPET as an indicator of exercise capacity. Our expectation is to enroll 270 patients, assigned to aficamten or placebo alongside standard of care, randomized at a 1:1 ratio. Given the positive Cohort 3 results from Redwood-HCM, patients whose background therapy includes disopyramide may now also take part. Every patient will get up to 4 escalating doses of aficamten or matching placebo, starting at 5 milligrams once daily and escalating to 10, 15 or 20 milligrams once daily as needed to reach target outflow track gradients. Dose escalation relies on echocardiography alone. Secondary objectives involve evaluations of change in KCCQ clinical symptom score and New York Heart Association Functional Class at week 12 and week 24. Although yesterday's press release summarizes the inclusion and exclusion criteria, one key criterion I want to highlight is that we'll enroll patients whose peak V02 is less than 80% of what's predicted for each patient, signaling a clear and objective reduction in exercise performance. As a result, we do expect to enroll a patient population whose decreased functional capacity is characterized by an objective rigorous measurement. We anticipate that enrollment for Sequoia-HCM will take roughly 1 year, so we expect to enroll through the duration of this year. In the meantime, we're continuing to enroll prior patients from Redwood-HCM into the open-label extension study, Redwood-HCM OLE. The bulk of Redwood HCM patients are opting to keep going in the open-label extension, with 37 patients — that's 37% — having joined so far at sites that are accepting new participants. We're eager to present the initial data cut from that open-label extension of Redwood HCM before this year is over. In addition, we intend to broaden the aficamten development program during this year. To start, our plan is to introduce a cohort 4 into Redwood-HCM so we can enroll symptomatic individuals who have nonobstructive HCM. Doing so will let us advance more quickly toward a possible pivotal clinical trial in nonobstructive HCM down the road. Enrollment for cohort 4 should get underway at multiple sites, beginning in the United States, very soon. Roughly 30 to 40 nonobstructive HCM patients will be included, enrolled in an open-label manner, receiving escalating doses of aficamten at 5, 10 or 15 milligrams guided by echocardiography. Safety and tolerability of aficamten in this population will be the primary objective, though we will also assess biomarker and symptom responses. Once we announce that Cohort 4 is accepting enrollment, we'll share further specifics about its design. Next, we intend to launch another Phase III clinical trial of aficamten in obstructive HCM later in 2022, so we can gain a better understanding of how it performs against the current standard of care therapy. Should aficamten receive potential initial approval — possibly founded on results from SEQUOIA-HCM — the findings of this trial could be folded into treatment guidelines or into a label expansion. Our intention to run a second Phase III clinical trial of aficamten serves as additional proof of how confident we are in aficamten's next-in-class profile. We're eager to share additional specifics regarding the growth of this vital aficamten development program as the year goes on. Now let's discuss reldesemtiv. Enrollment has carried on in COURAGE-ALS, the Phase III clinical trial of reldesemtiv for ALS. As a reminder, this is a sizable international trial set to enroll 555 ALS patients across the US, Canada, Australia, and Europe. It is informed by findings from FORTITUDE-ALS, the Phase II clinical trial, which demonstrated that patients across all reldesemtiv dose groups had less disease progression compared with those on placebo, with bigger and clinically meaningful differences appearing as time passed. Over the last quarter, we shared data from our ALS program at the International Symposium on ALS/MND. One of those presentations covered an analysis of baseline characteristics among the first 27 patients enrolled in COURAGE-ALS, revealing that most patients enrolled at the time of the analysis were middle progressors or fast progressors, exactly as the inclusion criteria of COURAGE-ALS intended, in order to boost the sensitivity of detecting a treatment effect. While we keep enrolling patients into what could be a pivotal clinical trial during this year, our expectation is that the data monitoring committee will carry out the trial's first interim analysis. That analysis is designed to evaluate futility, and it gets triggered 12 weeks after roughly 1/3 or a greater proportion of the planned patient count has been randomized. Our enthusiasm about what COURAGE-ALS might bring to ALS patients remains strong. Those patients, along with their advocacy organizations, are battling relentlessly to advance the creation of new treatments for what is genuinely a dreadful illness. Every single day, these patients keep inspiring us. Having said that, I'll hand the call over to Andrew.

Andrew Callos

executive
#5

Appreciate that, Stuart. Through Q4, we kept strengthening our commercial skills, systems, teams, and infrastructure even as we carried out our US go-to-market plan for omecamtiv mecarbil in the areas of market access, sales, and marketing. On market access, one early step forward involves advancing our pricing approach and distribution model, and we're still in discussions with every major payer, with intentions to broaden those payer conversations so they cover the GALACTIC-HF findings over the next several months. Two, now that our marketing group is assembled, we've completed both the brand strategy and the product positioning, which calls attention to what omecamtiv mecarbil offers and the way it serves an unmet need when treating heart failure with reduced ejection fraction, and work on our launch campaign keeps moving ahead. Last, efforts that support standing up and rolling out our sales force for the possible launch are ongoing; we've settled on the size and structure of that sales force. On top of that, important customers have been pinpointed among hospitals and cardiologists, and field territory boundaries have been laid out; we anticipate a sales force of roughly 200 FTEs, and keeping with our gated approach, sales reps will be brought on only once the FDA approves the drug. As we've said before, our plan rests on this gated build, staying careful with spending and kicking off work that aligns with major derisking milestones. The FDA's recent acceptance of our NDA is one such milestone, and it has set off the beginning of specific activities plus some extra hiring for key roles with longer lead times, such as first-line field managers, sales operations, commercial learning and development, along with additional growth of our ETOR, patient services, and access distribution strategy. Even so, our total team will reach only about 1/3 of the headcount we expect after approval, since most of our spending and FTEs won't come until approval, including bringing on our field representatives, buying media, and running patient support programs. On aficamten, we spent the last quarter working with global health technology assessment bodies to gain a clearer picture of the value drivers that would help secure access in major European markets. Come 2022, we'll finish our US go-to-market strategy for aficamten and keep carrying out market research alongside payers, physicians, and patients to shape this possible entry as a new therapy for hypertrophic cardiomyopathy; and with that, I'll hand the call to Robert Wong.

Robert Wong

executive
#6

Appreciate that, Andrew. Let me walk through the cash revenue and spending picture for Q4 2021. When the fourth quarter closed, we had $623.7 million sitting in cash and investments. That figure leaves out $150 million in proceeds that came in from deals we completed in late 2021 and early 2022. Most of our Q4 2021 revenue was driven by $54.9 million in license revenue recognized from the Ji Xing transaction. R&D expenses for the fourth quarter of 2021 climbed to $43.5 million, compared with $29.2 million in Q4 2020 — the main drivers being greater spending on clinical development for our cardiac muscle inhibitor programs, COURAGE-ALS, facility costs, and regulatory filing expenses. Over 60% of our R&D expenses came from our cardiovascular programs, while the rest went to our skeletal muscle programs and early research work. G&A expenses in Q4 2021 totaled $33.8 million, rising from $13.9 million in Q4 2020, largely because of higher outside service spending tied to preparing for a possible commercial launch of omecamtiv mecarbil, plus greater personnel-related costs, including stock-based compensation, and facility expenses for our new headquarters. With that, Ching will now go over our financial outlook and corporate development strategy.

Ching Jaw

executive
#7

Appreciate that, Robert. We came out today with our financial guidance for 2022. For 2022, the company expects revenue to land somewhere between $20 million and $25 million. Operating expenses should fall in a range of $380 million to $400 million, while net cash utilization is projected at roughly $365 million to $385 million. Right now we're sitting on a cash balance of about $724 million, and when you add the extra committed capital we expect to receive from Royalty Pharma once the first patient gets dosed in SEQUOIA-HCM, that gives us over 2 years of runway, based on the operating expense and net cash utilization projections for 2022. With the PDUFA date set for November 30 for omecamtiv mecarbil, and given how we plan to bring on the bulk of the sales force only after NDA approval, I'm anticipating a fairly gradual build in commercial spending during 2022. Take the sales and marketing costs tied to the omecamtiv mecarbil commercial launch — things like the sales force, media buying and the patient support program — most of that won't be spent until 2023, assuming omecamtiv mecarbil gets the green light late in 2022. So we don't anticipate any meaningful spending increases tied to post-approval activity before 2023. Two recent transactions underpin our solid balance sheet. In the fourth quarter, we told you about broadening our collaboration with Ji Xing Pharmaceuticals through an exclusive license and collaboration agreement covering development and commercialization of omecamtiv mecarbil for HFrEF in Greater China. Cytokinetics also signed a common stock purchase agreement allowing for sales — allowing for the sale and issuance to entities affiliated with RTW Investments of Cytokinetics common stock shares, with a total purchase price of $20 million at $39.125 per share; then in January 2022, we announced Royalty Pharma would supply Cytokinetics with long-term capital of up to $300 million, mainly to back the possible commercialization of omecamtiv mecarbil and continued development of aficamten. That capital comes to us across 5 tranches, starting with an initial tranche of $50 million, which we got when the deal closed, plus 4 more tranches. Those 4 remaining tranches, adding up to $250 million, become available in 25 million increments, subject to certain conditions and tied to specific milestones for omecamtiv mecarbil and aficamten. Every tranche Cytokinetics draws down is followed by an interest-free payment free period of 6 calendar quarters, and after that, equal installment repayments kick in across the next 34 calendar quarters. Interest plus principal repayment comes to 1.9x whatever amount is drawn. On top of that, Royalty Pharma is buying from Cytokinetics a revenue participation right on aficamten — 4.5% on sales up to $1 billion and 3.5% on sales beyond $1 billion, with certain step-downs applying. In return, Royalty Pharma will pay Cytokinetics up to $150 million in total, which includes $50 million at closing plus 2 more 50 million tranches, each one conditional on kicking off potential pivotal clinical trials for obstructive HCM and non-obstructive HCM, respectively. As in prior years, our goal is to finish 2022 with a forward cash runway exceeding 2 years, reflecting the possibility of higher spending across 2023 and 2024 to back the planned commercial launch of omecamtiv mecarbil along with our broader R&D pipeline. Once more in 2022, we anticipate seeking further business development, plus possible financing and/or other corporate development transactions. With that said, I'll hand the call back to Robert Baum.

Robert Blum

executive
#8

Thanks, Ching. We’re anticipating that 2022 is going to be yet another year of major transformation for this organization. Everything we’ve done in Q4 of 2021 and in the first stretch of this year has positioned us nicely to deliver on the bold objectives laid out in Vision 2025 — starting with the possible regulatory clearance for what could be our very first medicine, plus growing our development efforts for aficamten, together with momentum on reldesemtiv, earlier-stage candidates moving into the clinic, and CK-136 progressing through clinical work. On top of that, as Ching noted, we’re happy about the licensing deal we recently signed for omecamtiv mecarbil in China. Like we’ve said, our plan is to bring omecamtiv mecarbil to market in the US on our own, though we are actively looking into ways we might partner on omecamtiv mecarbil in Europe and Japan, and we’re staying committed to long-term approaches for thoughtfully growing our company; we’re eager to say more about those corporate development plans down the road and over the course of this year. Now let me walk through the milestones we anticipate for 2022. When it comes to omecamtiv mecarbil, we’re looking to launch omecamtiv mecarbil in the United States, assuming possible FDA approval, which could arrive in Q4 2022. For aficamten, we plan to keep enrolling in SEQUOIA-HCM all through 2022. We expect to start enrolling nonobstructive HCM patients in cohort 4 of Redwood-HCM during this first quarter of 2022, and we anticipate kicking off a second Phase III clinical trial of aficamten in obstructive HCM later in the second half of 2022. Also, we expect to report data from the open label extension study for patients finishing Redwood HCM over the course of 2022. Regarding CK-136, we intend to restart the development program this year, 2022. For reldesemtiv, we expect the data monitoring committee to carry out its first interim analysis from COURAGE-ALS during 2022. And when it comes to ongoing research, we plan to move forward with new muscle-directed compounds and run IND-enabling studies for 1 to 2 potential drug candidates within this calendar year. Operator, with that, let’s go ahead and open the call for questions, please. We will now begin our question-and-answer session. <<operator_script>> Our first question will come from the line of Carter Gould with Barclays.

Carter Gould

analyst
#9

Our question concerns the choice to start the second Phase III trial for aficamten. Could you describe what will make this study distinct from Sequoia; and next, did this come about because the FDA or EMA asked for it?

Robert Blum

executive
#10

I'll begin, then hand things to Fady and Stuart. First off, no request from FDA prompted this. Instead, it highlights our belief in a next-in-class candidate, and we feel it's our duty to move the field forward in a way that might eventually support broader labeling, and aficamten gives us that chance; we won't go into much detail about its design at this point, but I'll turn to Fady and Stuart in case they wish to say more. Maybe I'll add that many significant scientific questions exist around therapeutic intervention for this patient population. SEQUOIA doesn't resolve all of them, though — yet further trials could help clarify where therapy might fit in guidelines or perhaps work in other circumstances; and as Robert mentioned, once we near launching this Phase III trial, more specifics will come. Still, we want to stress that no specific regulator feedback drove this.

Justin Kim

analyst
#11

I’ll keep it to a few items. I realize the team has only recently received the METEOR data, but I wanted to ask whether anything has stood out regarding peak VO2 reliability when used as an endpoint, especially through COVID-19? I’m simply trying to get a sense of whether any variation showed up depending on whether patients enrolled before the pandemic or while it was ongoing.

Robert Blum

executive
#12

That’s difficult to address without being in a position to disclose the data, which we’ll be doing before long at ACC. That said, perhaps Fady would like to comment on it?

Fady Malik

executive
#13

Yeah. I believe that's a solid question, since clearly we ran this study through a difficult period. I'd say the data quality came out remarkably strong given that situation, with hardly any CPET tests absent, and the quality, the variability and so on ended up quite near our projections. Generally speaking, cardiopulmonary exercise testing appears to be a highly objective way of measuring exercise capacity, and there isn't really much of a placebo effect in play either. So I'd say overall, the modality, and even with the pandemic, was still a meaningful outcome in this trial.

Justin Kim

analyst
#14

All right, that's helpful. Just one more thing about the fourth cohort, if I could. Since there aren't many rental choices available for symptomatic nonobstructive disease, do you think these patients might lean more toward the severe end among nonobstructive cases? I'm simply interested in learning which particular clinical activity measures could move the programs forward into broader, larger studies.

Robert Blum

executive
#15

Fady, would you like to handle that?

Fady Malik

executive
#16

I'll kick things off, and then hand things over to Stuart. In my view, that remains an open question. I believe what you observe is the same range of symptoms found in obstructive individuals, and those symptoms are going to be milder, along with patients who are hit harder. Depending on the criteria we use for enrollment, we will lean somewhat toward the group with more symptoms; however, I don't see a fundamental reason to do so—my sense is that these are distinct. Stuart, is there anything you'd like to add, or…

Stuart Kupfer

executive
#17

Yeah, absolutely — I'd say the factor itself being symptomatic really points to how far the disease has advanced, and we're also going to monitor circulating biomarkers in order to capture how severe the disease is. So that, in essence, is going to tell us how we move forward and how these patients do, or what the safety profile looks like, when it comes to the next study.

Anupam Rama

analyst
#18

To pick up where Carter left off regarding the second aficamten obstructive study — I realize you won't go into much detail about how the trials are designed, but will these involve two separate or entirely distinct groups of patients that you plan to enroll, let's say, in Sequoia compared with the second Phase III? Or is there going to be a degree of overlap when it comes to patient phenotype?

Robert Blum

executive
#19

That's a fair question. Clearly, given that both of them will target individuals who have obstructive HCM, some overlap is inevitable, yet the two are genuinely meant to pose and resolve distinct questions. Neither ought to depend on the other. And as we've said previously, our expectation is that SEQUOIA-HCM will stand alone as adequate and pivotal for possible registration. That may be all I can offer at this point short of going deeper into the design, which is not something we plan to do today. Fady, is there anything you'd like to add?

Fady Malik

executive
#20

No, I believe that's — for me, it's obvious, I believe we will — those will be obstructive HCM patients. And once more, I think there are numerous scientific questions, to put it that way. In terms of how therapy should be implemented for these patients, and what could be anticipated from that therapy, you could likely come up with a number of them on your own that you'd want answered. We don't want to — we do want to signal that we intend to look into a few of those so the field is better informed. However, at this stage in the process, we simply aren't prepared to reveal our plans.

Robert Blum

executive
#21

There's no intent on our part to be evasive. What we're doing is simply making sure everything is in order prior to laying out how it's structured, since our goal is to get SEQUOIA HCM up and running, and after that we'll be in a position before long to give more detail about the shape of this upcoming trial.

Akash Tewari

analyst
#22

This is < > calling in for Akash. Could you share additional detail about the reason the team has enrolled in a further Phase III trial of aficamten? Might you possibly conduct a head-to-head trial against mava? In addition, what will the expense of this trial be? Our next question is that earlier we observed mava as a long-term extension for nonobstructive HCM even while patients were on a stable dose. 21% of patients in the long-term extension experienced their LVEF falling below 50%. Can you provide any insight regarding how stable LVEF is for Redwood among patients in Cohort 1 and 2? Did any of these patients require a dose adjustment following 10 weeks, and have they had their LVEF fall below 50%?

Robert Blum

executive
#23

So I will handle the first one and perhaps ask Fady and Stuart to address the data from the open-label extension. As before, we will not discuss the particular design of this second Phase III trial. What I can say is that the costs tied to that trial are more likely to be incurred in 2023 rather than 2022. We do anticipate launching the second Phase III trial during this year, yet most of that spending will not affect our P&L during this year. I will not say whether it will be a head-to-head comparison with another drug, because that is not our aim today. Rather, our aim is to state that because we have now raised additional capital and because of our confidence in its next-in-class profile, we do believe it is our obligation to advance the category as should be enabling of potential further expansions in labeling in accordance with standard of care. And I think that is the best we can manage today. Fady or Stuart, would you like to discuss LVEF and the open-label extension?

Fady Malik

executive
#24

Okay. So within the next year, we intend to share results from an open-label extension study. At this point, we won't get into specifics — not any specifics today. What I can tell you is that data coming out of the initial 3 cohorts in Redwood-HCM strikes me as genuinely useful for understanding what could lie ahead over a longer horizon. As you might remember, across all of those cohorts, not a single patient needed to have treatment stopped or paused. That, I think, reflects how aficamten has a fairly broad therapeutic index. And once again, this is something we'll simply need to keep tracking as we gather more extended experience from the open-label extension of Redwood, plus SEQUOIA-HCM, a trial lasting 24 weeks.

Robert Wong

executive
#25

We shouldn't be the ones to weigh in on a drug candidate belonging to some other company and how that candidate is doing in a trial. What I'm able to share is the same thing Stuart mentioned a moment ago: we have a fair degree of confidence that the dosing plus the dose regimen, when guided by echo, showed in cohorts 1, 2 and 3 that it yielded exposures that were predictable and could be sustained.

Charles Duncan

analyst
#26

Robert, congratulations to you and your colleagues regarding the OMI NDA being accepted, plus the core start. I believe it relates to exercise capacity. So I have a question with two parts for Fady, and afterward a follow-up I'd like to pose to Ching. About the two-part exercise capacity question: because of the meteoric results, I'm curious how you can — how would you square that with the mechanism we discussed previously? Also, do you believe that might affect in any manner how clinical value is perceived for OMI? Then the second part concerns how the METEORIC study was conducted — were there any lessons from it that could influence or assist you in running this SEQUOIA study more effectively with aficamten?

Robert Blum

executive
#27

Those are good questions. Fady?

Fady Malik

executive
#28

Regarding what we observed in New York — specifically the absence of any impact on exercise tolerance — I believe a few possible explanations exist. Obviously, these are just speculations and ought not to be interpreted as any indication about the results. But looking at it, we definitely know omecamtiv mecarbil boosts exercise performance — I mean, cardiac performance. That has been demonstrated in additional clinical trials. However, among the patients enrolled in New York, who were comparatively stable, the real question becomes: to what degree is their cardiac performance restricting their ability to exercise? Keep in mind, these individuals have heart failure outcomes alongside considerable skeletal muscle dysfunction — you observe energetic deficits in skeletal muscle that accompany cardiac muscle issues. How the 2 contribute relative to one another, I'd say, isn't particularly well grasped. You plainly notice that with other drugs or other — or instead, let me say mechanical approaches or device-based approaches that enhance cardiac function, which are proven to help certain aspects of exercise performance — those tend to have considerably bigger effects on cardiac performance. So perhaps the rise in cardiac performance caused by this drug simply isn't big enough for an improvement to show up in skeletal muscle performance among these patients — or instead, in exercise performance among these patients.

Charles Duncan

analyst
#29

Understood. Then what about the danger to afi concerning how that trial is carried out?

Fady Malik

executive
#30

Right. I suppose — the remaining piece was really whether it has any bearing on omecamtiv's clinical worth, and my view is not much, honestly. Clinical outcomes have drawn most of the attention. Obviously, a positive study would have been welcome, and it would have set omecamtiv apart from other heart failure therapies that do affect clinical outcomes; yet with those therapies, you similarly lack any actual effect on exercise capacity. So we haven't — at least our market research and such hasn't revealed a major downside from lacking a benefit in that area. Regarding what we take away for SEQUOIA, there's definitely a substantial benefit in having run a big international Phase III trial with an endpoint measured identically to the one we'll use to run Sequoia. So by now we've gained considerable experience about the ways the test can fail, how sites ought to be trained, what you should be watching for, and how sites get qualified — everything like that. And I'd add that METEORIC, judging by the data quality and so forth, was a truly superbly executed study, and I believe that positions us well to accomplish the same with Sequoia.

Charles Duncan

analyst
#31

All right. Then, turning quickly to Ching about the expense guidance, I appreciate that you gave full year guidance for this year, and you're probably not ready to do that for next year. But I suppose I'm just wondering, regarding this year's expense, would you expect a step function or an incremental rise next year? And then, of the $365 million to $385 million in expenses, roughly what percentage will go toward omecamtiv marketing?

Ching Jaw

executive
#32

So, for the first part of your question, as Andrew laid out on the call, we don't expect to start hiring the sales force until after NDA approval comes through, which now looks likely to be at the end of November. So, looking at 2022, I don't expect meaningful increases in 2022 compared with the range we provided today. In 2023, those sales force members we brought on in 2022 will accrue full year expenses. So I do expect a significant headcount increase — headcount expense increase in 2023, on top of all the marketing spend, media buys and patient support program, et cetera. So we're not ready to provide 2023 guidance, but I think it's fair to say that expenses in 2023 are expected to be higher than 2022; and as for percent of the range, we're not breaking it down today, but as Andrew laid out, the spending in 2022 in commercial for omecamtiv mecarbil is roughly 1/3 of the total spend that we will anticipate once omecamtiv is launched and the commercial spending reaches steady state.

Robert Blum

executive
#33

When you ask about marketing in 2022, what percentage did it represent? Honestly, the amount we put toward marketing is fairly small. But if you're talking about commercial more broadly — including supply chain, distribution, logistics, plus other commercial costs outside of marketing — then it does get somewhat more significant, though it remains much smaller than even a single one of our clinical trials. So my focus wouldn't be on marketing spend in 2022 as a major factor behind the rise in spending. A lot of that increase in 2022 compared with 2021, for example, comes from having a full year of COURAGE-ALS, a full year of SEQUOIA, and the extra clinical trials you heard about today. As for why we decided to pursue the deals we did in December and January, it was largely so we could put ourselves in a position to substantially expand the development program for aficamten, as we announced today.

Charles Duncan

analyst
#34

Thanks, Robert — that's useful. I'm not really worried about costs, and I'm eager to see more business development coming from your team.

Robert Palermo

analyst
#35

Rob here, filling in for Madhu. Could you remind us what the futility analysis criteria are for the possible second half, in terms of COURAGE-ALS?

Robert Blum

executive
#36

Of course. I'll hand that over to Fady and Stuart.

Stuart Kupfer

executive
#37

So the question is about the upcoming futility analysis?

Robert Palermo

analyst
#38

Yes, that's right. What are the criteria?

Stuart Kupfer

executive
#39

Well, like we said during this call, we won't carry that out until roughly 1/3 of the patients have completed 12 weeks of treatment; it's a fairly uncomplicated futility analysis. Basically, what we're evaluating is whether reldesemtiv is demonstrating a trend toward greater benefit compared with placebo. I mean, that's kind of the — that's sort of the key point; so it's not an especially high bar, but we definitely want to have some degree of confidence before we keep moving the trial forward. So that's really what the first interim is meant to achieve.

Robert Blum

executive
#40

Keeping in mind that the study design also includes a second interim analysis, this initial futility check is mainly meant to confirm there aren't any negative effects from adding reldesemtiv on top of standard of care. So, as Stuart mentioned, the threshold isn't especially demanding; we anticipate getting through it. What we're aiming for is confidence that our results are at minimum as good as what FORTITUDE-ALS showed, and then to observe those effects potentially building up across extended timeframes. That means the first futility check sets a lower threshold, while the subsequent interim could establish a higher one.

Melina Santoro

analyst
#41

This is Melina calling in for Jeff. So I suppose this is just a follow-up regarding COURAGE. Beyond the number of participants, could you share a bit more about what we're doing within the study design elements that should improve the odds of success? Then our second question, a quick one about CK-136. Was the decision to reactivate that program later this year essentially a matter of reprioritization? Or how did you arrive at the choice to bring that program back to life?

Robert Blum

executive
#42

Sure. I'll take the second one first. We wanted to be certain we had the extra resources, both cash and otherwise, to move CK-136 ahead. As a reminder, this compound was one that had previously been partnered with Amgen, and under our Amgen collaboration we had to make provisions for the transition so we could fully move it forward on our own, and that's exactly what we're doing now. But in the second half of 2021, we were ready for this, partly to make sure we could finish what we started. Our plan is to resume from where CK-136 stopped under our Amgen collaboration, push it ahead in Phase I, and be positioned to make a call on potential Phase II as soon as possible; so you'll be hearing more regarding CK-136. We're quite enthusiastic about this molecule. It's a novel mechanism that we believe gives it a chance to be studied in some key indications with high unmet need, and so you'll hear more on that this year; as for COURAGE-ALS in your first question, I'll hand it over to Stuart and Fady, but let me begin by noting that the number of participants is merely one element we're examining, drawing on learnings from FORTITUDE-ALS and from discussions with regulatory authorities, and we've built COURAGE-ALS to enrich for what we hope will be a treatment effect based on things we've observed before. Stuart and Fady, maybe you can expand on that.

Stuart Kupfer

executive
#43

Absolutely, that's correct. What FORTITUDE-ALS taught us, I believe, actually makes the study design more robust and raises the likelihood of success — and dose selection is certainly one part of that, correct? A dose of 300 milligrams BID was what we chose. In terms of the benefit risk profile, we believe that was optimal. Another key component, which Robert was hinting at, involves enriching the population for patients who are medium or fast progressors. I brought this up on the call — while the call was happening. The rationale there rests on, once again, findings from FORTITUDE indicating that those patients are in fact showing the greatest magnitude of treatment benefit; so the patient population in which there was less progression relative to placebo. This is roughly what you'd anticipate being the stronger capacity to detect treatment effect in a population progressing at a faster rate. So in a sense it boosts sensitivity, the likelihood of demonstrating a treatment benefit. There are additional components too. I won't delve into extensive detail, but a great deal of thought went into how the study was designed regarding the ability of patients to actually engage and participate. Obviously, these patients struggle a great deal with mobility, and simply being for transportation to the clinic is extremely difficult. So the majority of our visits are in fact remote visits. And so I think relative to other trials that have been run in ALS, this one is comparatively easy for patients to participate in; so it carries significantly less burden. And ideally, that will lead to better patient retention and engagement.

Sean McCutcheon

analyst
#44

Sean McCutcheon (Raymond James; Biotech Equity Research Associate): Sean here, filling in for Dane. Perhaps it would help to get a bit more specificity regarding the endpoints in Redwood cohort 4. In what ways are they similar to and different from the MAVERICK study? And then, how might those secondary endpoints, perhaps the functional ones, guide you toward a possible pivotal?

Robert Blum

executive
#45

Sure. I believe MAVERICK taught us a few lessons. In my view it was a solid study, and it shows BNP works as a meaningful biomarker for this mechanism of action within this population, yet we can also go further, which is what we plan to do in Cohort 4. Very soon, we will be putting the study's design and endpoints up on clinicaltrials.gov. That said, Fady or Stuart, is there anything more you would like to add right now?

Stuart Kupfer

executive
#46

No, I was basically just going to say that I agree with what Robert said, and we'll go into more detail once we're ready to begin. But as far as the goals go—safety, tolerability, and those findings—I think you can get a sense of the types of endpoints we'll be including.

Jason Butler

analyst
#47

Robert, I have a single question regarding omecamtiv. Regarding that sales team of 200 people, could you tell us what share of the intended audience you're able to prioritize right away, and how that splits across hospitals or doctors who devote considerable time to inpatient settings as opposed to outpatient heart failure clinics?

Robert Blum

executive
#48

Of course. Let's have Andrew address that, if you would.

Andrew Callos

executive
#49

Alright, thank you for asking that. Regarding our sales team, our attention is on the bulk of cardiologists handling patients whose heart failure is getting worse. My guess is that figure lands somewhere between 60% and 70%. Naturally, there's certain crossover between doctors who provide in-hospital treatment versus those who simply devote time within hospital settings. As a result, you'll get a sort of repeated reach for those physicians working in both places. Then, on the last part of what you asked about, when it comes to how things are sized proportionally, roughly 60 to 65% of our people — looking purely at staffing numbers — are aimed at outpatient cardiology, while the rest are aimed at hospitals. Hospitals are much simpler to reach; we're targeting a bit under 1,000 of them, along with fewer than 10,000 cardiologists, and perhaps that's simply one more way to look at it.

Mike Linden

analyst
#50

This is Mike Linden, filling in for Salim. If I could, a few questions about aficamten. To start with SEQUOIA, I realize it's still early days, since enrollment has only just begun. Given that mavacamten could be approved in April, how comfortable are you with how SEQUOIA's enrollment will go in the U.S.? Or what factors might lead patients to sign up anyway, when they know they could get placebo rather than having mavacamten available? Then my second aficamten question — I understand you're unable to discuss pricing, and it's quite early — but broadly, in the Obstructive HCM market, there appears to be some inconsistency in how peak sales are modeled for mavacamten compared with aficamten. Price is clearly one of the main variables there. So there's debate about roughly where the price lands, and the range people tend to focus on looks fairly wide, with ICER having weighed in and mentioned mavacamten at 12,000 to 15,000 a year. As I recall, Myocardia's figures used to be much higher. So, at a general level, just to help us grasp the dollar size of the Obstructive market, which market comp should we use, or what framework?

Robert Blum

executive
#51

Sure; let's take your second question first, and then I'll hand it to Andrew. I'd say that for a good while now, we've been indicating that price and value in this category differ from what Myocardia has sometimes suggested and Wall Street analysts have repeated; we're paying attention to what ICER said. We also figure BMS is quite shrewd about such matters and understands what it's doing regarding how it will eventually set pricing, consistent with anticipated demand and with value assumptions too. Where that ends up landing on gross to net, I think, is something we'll be watching. Naturally, we have our own scenarios. But since this product has only just moved into Phase III, please forgive us if we won't reveal anything about how we plan to eventually set pricing. Andrew, is there anything you'd like to add?

Andrew Callos

executive
#52

Yeah. I suppose the sole point that might be worth adding when you think about forecasting is that it definitely won't fall within the ICER price range. I'd say — my guess is it also won't land in that upper bracket you've observed. So you're likely looking at something in between. A useful comparison is always to examine how price and prevalence relate. This condition is rare. At present, fewer than 200,000 patients in the U.S. have a diagnosis. So perhaps that offers one more hint or signal regarding where pricing might land. And if you think about projecting forward, there really are — symptomatic therapies exist. Surgery, clearly, is another option. So there really isn't an effective pharmaceutical option addressing the underlying condition until these — and only if these products were to be approved; so you take that 190,000 prevalence figure, and if you accept that actual prevalence runs 3x to 4x higher simply because diagnosis rates keep climbing over time, and you sort of consider that price level, my sense is that eventually, most patients are going to receive treatment. So ideally those are some inputs or considerations for modeling; but past that, I won't say much more.

Robert Blum

executive
#53

Regarding your initial inquiry about enrollment, the estimate Stuart provided—roughly 12 months, more or less—was made while fully aware that we anticipate mavacamten getting approved in Q2. I genuinely believe that medication will probably be well received and will have a successful launch. I think BMS will do a good job bringing that first-in-class therapy to market. Yet even so, we remain quite confident in our forecasts for how SEQUOIA will recruit participants, partly since aficamten offers a next-in-class profile, and partly because within a clinical trial, patients gain access to care and resource intensity that isn't consistently offered outside of a trial setting, particularly as would occur through an open-label extension. Still, we aren't relying solely on the U.S. Naturally, we're also enrolling individuals in other regions. Fady or Stuart, is there anything you'd like to add?

Stuart Kupfer

executive
#54

Right, so I would say that those individuals who took part in SEQUOIA will obviously be able to join the open-label extension, correct? Therefore, getting aficamten for extended therapy without paying anything is a benefit. And I believe that's something that could be attractive too.

Fady Malik

executive
#55

There's another point worth remembering here: this isn't a condition that moves quickly and kills, and that fact makes enrollment quite hard when an approved therapy already exists on the market. Even so, many of these individuals have endured their symptoms for years at a stretch, and deciding between joining a study or starting a different medication is, of course, up to them. Still, as Stuart pointed out, there's something fairly appealing about enrolling in a trial and then getting open-label therapy over the long term once that study wraps up, without paying anything themselves. So we'll watch and see how it plays out.

Robert Blum

executive
#56

A substantial number of clinical trial sites will be brought on board for SEQUOIA. That contributes significantly to our confidence that we can get all the patients enrolled in approximately 1 year.

Yasmeen Rahimi

analyst
#57

Robert, two things from me. I fully back your choice to give us additional detail regarding how the second aficamten HCM trial is designed. Still, Fady, I'd love to hear from you — could you perhaps walk us through the obstructive HCM patient population in greater depth? How exactly do we break these patients into groups? I realize you mentioned mild to moderate when it comes to symptoms. But it would help if you could get more granular about the disease spectrum. Then my other question concerns the non-obstructive HCM trial. Since a different myosin binding inhibitor failed in non-obstructive HCM, how confident are you that success can be achieved in this population?

Fady Malik

executive
#58

Sure, Yasmeen. Good to talk to you. With oHCM, I'd say there's a broad disease spectrum. Some patients have relatively mild obstruction, yet other regions of their ventricle might still contribute to abnormal filling and possibly symptoms. Some patients show high obstruction levels, but perhaps few symptoms. Naturally, you also have those with high obstruction plus meaningful symptoms; and lastly, there are patients whose disease isn't truly controlled by medical therapy, leaving them to weigh surgical or invasive choices such as septal ablation. So in a nutshell, that captures the patient spectrum, and for aficamten studies — and in this field generally — our focus is really the symptomatic patients who have a significant degree of obstruction. That said, other populations deserve consideration too. On your second question about nHCM, non-obstructive HCM, these patients by definition lack obstruction to blood flow leaving the heart, but their ventricles are thickened with filling problems. You saw MAVERICK as a failure, yet I'd urge caution in how you interpret that. MAVERICK was relatively small and not very long. It also carried a lot of clinical endpoints, which were probably underpowered for assessing clinical events or clinical outcomes, symptoms or exercise performance. If exercise performance could be measured in a 50-person study, SEQUOIA in 270 people wouldn't be necessary; and do you know, in this population, whether 16 weeks of treatment suffices versus needing far longer treatment, 6 months to 12 months, for instance. So I think the key in a Phase II study of nHCM is asking whether there are signals that read on the potential in a Phase III trial to impact a more clinically relevant outcome. Could you potentially observe signs of reverse remodeling, could you potentially observe shifts in biomarkers and other such things, and then transition into Phase III in order to more effectively design and carry out a Phase III trial, in which you examine that — examine how those things affect clinically meaningful endpoints. So, I don't see — I believe MAVERICK indicated how the mechanism of action affects specific biomarkers, which might be predictive of long-term benefit in this space; but clearly, we still need to construct that bridge from Phase I to Phase III.

Rohit Bhasin

analyst
#59

Rohit Bhasin (Needham & Company; Equity Research Associate): Rohit here, filling in for Serge. About the METEORIC-HF trial — did the results of that study shift how you're viewing possible spending on marketing omecamtiv once it gets approved?

Robert Blum

executive
#60

I'll take that first and perhaps hand it to Andrew, though my answer is absolutely not; the choices about what we're doing were driven by GALACTIC and by GALACTIC only; and although we'd hoped METEORIC would show effects adding to those from GALACTIC, having neutral results in METEORIC doesn't take away from what makes us enthusiastic about omecamtiv based on GALACTIC. What I can tell you is that omecamtiv is now among a lengthy group of heart failure therapies that haven't shown gains in exercise stamina; and though we believed we had a solid therapeutic hypothesis worth testing, we're confident the METEORIC findings indicate this drug candidate, like numerous others, isn't producing an impact on exercise stamina. Yet it has already shown, in a considerably bigger clinical trial, GALACTIC — far, far bigger, with far longer treatment periods — that it affected hard clinical outcomes, among them a composite of death and heart failure-related events, and our spending choices rest on that. Andrew, is there anything you'd like to add?

Andrew Callos

executive
#61

Robert, your explanation was thorough. Perhaps the sole point I'd include is that we'd also conducted market research with physicians to gauge their reactions to METEORIC—whether positive, neutral, or negative. If it had come out positive, that would definitely have added value, just as Robert outlined. However, considering the final result, we don't expect any effect whatsoever, and nothing shifts regarding our positioning, nothing in our broader strategy, nothing about how much we put into field force size. Everything proceeds according to plan.

Robert Blum

executive
#62

And because of that, we're putting money not only into commercialization but also into managing the product throughout its life cycle. When we consider the possibility that omecamtiv gets approved at some point ahead, we're already thinking about additional studies that we believe we'd want to start during 2023 and 2024.

Emanuela Branchetti

analyst
#63

Could you assist us in assessing how much the clinical community knows about omecamtiv? If this drug gets approved, what factors do you see as crucial for encouraging its uptake? For instance, how much time do you expect before omecamtiv appears in American guidelines? Also, would that be a major factor following approval?

Robert Blum

executive
#64

That's a solid question. Awareness depends on various elements, such as the level of clinical research activity and how far those investigators are personally involved in treating heart failure patients. Given that omecamtiv mecarbil has been in development both in the United States and worldwide, over such a long period and through numerous studies, awareness levels are fairly elevated. Andrew can provide more detailed, quantitative insights from market research on this. I should also mention that since we plan to commercialize omecamtiv mecarbil, guidelines will play a significant role. As Fady can discuss, guidelines are now being revised more often. We anticipate that omecamtiv will be included in guidelines soon after approval. That's one factor that might drive early uptake. Market access is another, and there we'll take a more cautious approach, as Andrew will explain. So let's have Andrew share his thoughts first, followed by Fady.

Andrew Callos

executive
#65

Sure. Regarding awareness, it's honestly quite strong given where omecamtiv mecarbil sits in terms of registration status. Without any prompting, roughly 1 in 10 cardiologists know about omecamtiv, which is genuinely high for unaided awareness when you lack a commercial footprint in the market. And more than half of cardiologists, once aided—when you simply mention the mechanism, and so on—are definitely familiar with it; so our awareness heading into a launch is really solid. As for adoption, a pattern you observe in essentially every launch is that adoption tends to be slow at the outset. Part of that stems from awareness, as you mentioned, and part comes from payer uptake occurring gradually. So we anticipate broad payer access around 12 to 14 months following launch. But we're certainly aware that uptake will be slow, perhaps through the first 12 or 14 months, while we begin building more of that payer access and patient access, particularly with Medicare, where most patients are, and there's a very clear timeline for securing Medicare access; so ideally that helps. Fady?

Fady Malik

executive
#66

Yes. Thank you, Andrew. Regarding the guidance documents, I believe, as Robert pointed out, that the groups responsible for those guidelines have recognized how much faster heart failure studies are now moving, along with the emergence of fresh findings that could shape how heart failure is treated, and at the same time the need to possibly revise those guidelines so that newly generated evidence gets included. So even though a full overhaul of the guidelines might happen every few years, I think the — especially those in the U.S. are starting to consider more modest revisions during the periods in between; and therefore, with the results we have, and above all with an approval, we would hope that guideline committees might explore where omecamtiv mecarbil could be added into the standard of care.

Robert Blum

executive
#67

Thanks, operator, and I appreciate everyone joining today. My closing remarks will be short; 2021 finished strongly for us. There was considerable advancement in our R&D pipeline and in getting ready for 2022; late last year and in the early portion of this one, we completed some important transactions that give us a sturdier balance sheet and additional cash runway going forward. And we've already begun this year well, given that omecamtiv's NDA was designated for standard review with a PDUFA date we expect later this year, along with Cohort 3 of REDWOOD-HCM and the launch of SEQUOIA-HCM. So all cylinders are firing, and we feel quite optimistic that this could be yet another transformational year; we're grateful for everyone's interest in the company and in the strides we're making. We're eager to keep you informed about that progress and our prospects across this year. With that, operator, we're ready to wrap up the call. Thank you so much.

Operator

operator
#68

This concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.